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Natural animal collagen and its recombinant collagen are favorable replacements in 
human tissue engineering due to their remarkable biomedical property. However, this 
exploitation is largely restricted due to the potential of immunogenicity and virus 
contamination. Exploring new ways to produce human collagen is a fundamental key 
to its biomedical and clinical application. All human fibrillar collagen molecules have 
three polypeptide chains constructed from a repeating Gly-Xaa-Yaa triplet, where Xaa 
and Yaa represent one random amino acid. Using cDNA techniques to modify several 
repeat sequences of the cDNA fragment, a novel human collagen named recombinant 
human-like collagen (HLC), with low immunogenicity and little risk from hidden virus 
can be engineered and notably tailored to specific applications. HLC was initially used 
as a coating to modify the tissue engineering scaffold, and then used as the scaffold 
after cross link agents were added to increase its mechanical strength. Due to its good 
biocompatibility, low immunogenicity, stabilised property and the ability of mass 
production, HLC has been widely considered to use in skin injury treatments, vascular 
scaffolds engineering, cartilage, bone defect repair, skincare, haemostatic sponge, and 
drug delivery including coating with medical nanoparticles. In this review, we 
symmetrically reviewed the development, recent advances in design and application of 
HLC, and other recombinant human collagen-based biomedicine potentials. For 
comparison and providing basic background information about the techniques, we start 
with recombinant human collagens. In the end, future improvements in using HLC are 
also discussed. 
 
Keywords: Recombinant human collagen, human-like collagen (HLC), tissue 
engineering, drug delivery, medical nanoparticle 
1. Introduction 
Collagen, a fibrillar protein, is found in abundance in the body and plays an important 
connective role in skin, joints, and bones [1]. Natural human collagens have been 
explored in biomedical and clinical applications, particularly in tissue repair, 
regeneration, and replacement but they are difficult to obtain [2]. The fact that collagen 
sponge converted from natural collagen solution after lyophilisation lacks mechanical 
strength and with unpredictable biodegradability [3] further hinders its applications in 
hard tissue. The replacement of natural human collagens with extracted animal 
collagens appears to be an avoidable natural solution but using animal collagen has the 
potential risk of immunogenicity and virus contamination, and its mechanical strength 
and biodegradability still remains an issue [4]. 
 
There are twenty-nine different collagens classified in eight families based on their 
structure, chain bonding, and locations in the human body [5]. They all have a simple 
repetitive (Gly-Xaa-Yaa)n sequence motif, where X and Y are often proline and 
hydroxyproline, that can be used as a building block for self-assembly into complex 
hierarchical structures such as fibrils, fibers, and bundles [5]. Using standard 
recombinant methods, targeted human collagen cDNA fragment is selected to use as a 
backbone gene [6]. This gene is then cloned into a selected expression vector and 
transformed into expression cells. After purification, recombinant human collagen is 
obtained [7-10]. This recombinant human collagen is very similar to the natural human 
collage and its purification process can potentially minimize or even eliminate viral 
contamination. As a result, the recombinant human collagen normally has a good 
biocompatibility such as low immunogenicity and little risk from the hidden virus [11]. 
Numerous commercially available collagens (e.g. FibroGen, CollPant, etc) have been 
developed over the years. Due to their improved properties, recombinant human 
collagen have been successfully used in biomedical engineering [12, 13], especially in 
skin repair, tendinopathy, cornea and some cardiac repair therapy [14-18].  
 
However, studies also find that recombinant human collagen lacks stability and often 
degrades quickly during the purification process [7-10]. These properties of 
recombinant human collagen make it difficult to be obtained and used. At the meantime, 
the low yield and high production costs limit its applications further. These are probable 
reasons why even though this standard recombinant method has been around for many 
years, it did not find, thus far, any widely used applications. On the contrary, utilizing 
native collagens from animal sources remains the main resource of applications. 
Therefore, a new approach is desperately needed. 
 
In 2002, Fan et al. modified several repeat sequences of human collagen cDNA 
fragment, designed a novel collagen sequence and expressed it as a novel recombinant 
human collagen [19-21]. They named it as ‘recombinant human-like collagen (HLC)’ 
(China patent number: ZL01106757.8). Briefly, the human collagen sequence template 
is modified through changing the Xaa and Yaa in the repeat peptide (Gly-Xaa-Yaa)n 
sequence [22-24]. Foremost, the isoelectric point (pI) could be adjusted higher or lower 
through changing the amino acids of the (Gly-Xaa-Yaa)n. This pI design therefore 
makes the HLC purification more achievable. Secondly, the hydrophilicity could also 
be adjusted though adding hydrophilic amino acid in the (Gly-Xaa-Yaa)n. Thirdly, 
additional lysines [25] within the (Gly-Xaa-Yaa)n can be further used to promote the 
cells adhesion. 
 
Notably, compared with the traditional recombinant human collagens, this novel HLC 
is more stable, degrades slowly, and therefore easy to purify [26-28]. Meanwhile, HLC 
scaffolds obtained through this method are suitable for cell homing and growth [11, 28]. 
Even strikingly, after many years of optimization on all producing process, the 
production of the HLCs is continuously increasing [20, 21, 29-32]. Currently, these 
HLCs can be put into mass production with a high yield of 14 g/L and small costs which 
facilitate its applications in hemostatic sponge, skin injury treatments and skincare. The 
ability of mass production also open opportunities to explore its applications in many 
other aspects of biomedical and clinical areas. 
 
This unique technique and great potential applications in biomedical and clinical 
sciences have attracted more and more research interests since our first publication in 
2002 [19]. In this paper, we review the development of HLC, the “hobbled” mass 
production venture and fast-moving recent advances on its applications. In addition, the 
prospects for further development of HLC for therapeutic-related applications are also 
evaluated. For comparison and providing basic background information about the 
techniques, we start with recombinant human collagens.  
2. Recombinant human collagens 
Collagens play essential roles in cell attachment, migration, proliferation and 
differentiation [1]. They are classified as twenty-nine different types and grouped into 
eight families according to their structures, chain bonding, and locations in the human 
body [1]. Different types of recombinant human collagens can be designed accordingly 
to their locations in the body to meet their different functions. For example, 
recombinant human collagen type I has been used as membranes for guided tissue 
regeneration due to its wide distribution in dermis, tendon, ligament, bone, and cornea 
[33, 34]. Similarly, recombinant human collagen type III has been used as haemostats 
and tissue sealants due to its wide presence in tendon, cornea, reticular fibers, cartilage, 
vessel wall, nucleus pulpous, bone, vitreous body, and skin [35-37]. There are different 
human collagens continuously being developed through recombinant systems for 
purposed use [38]. 
2.1 Expression of the Recombinant Human Collagen 
Typical expression systems used are mammalian cells [39], insect cells [40], transgenic 
tobacco [41, 42], transgenic mouse [43], and transgenic silkworms [44]. Microbial 
expression systems are also successfully employed to express various types of human 
collagens [45]. For example, human type I-III collagens have been successfully 
expressed by yeast pichia pastoris [8, 46-48], human type III collagen by Escherichia 
coli [49], hydroxylated human collagen III α1 chains by P. pastoris GS115 [50] and 
Escherichia coli [51], while recombinant human prolyl with human collagen a1 (III) 
chains has been co-expressed in two yeast systems [52]. Table 1 summarizes 
recombinant human collagens obtained using different expression systems (Table 1). 
 
Table 1. Recombinant human collagens 
Type Host Yield Reference 
Procollagen X HEK293 cell 50 mg/L Frischholz et al. [39] 
Procollagen I Insect cell 10~20 mg/L Myllyharju et al. [40] 
Collagen I Transgenic tobacco 200 mg procollagen per kg 
of fresh leaves. 
Stein et al. [41] 
Procollagen Transgenic mouse 50~200 mg/L John et al. [43] 
Procollagen III Transgenic 
Silkworms 
5 kg total collagen obtained 
from about 600 kg cocoon 
material 
Tomita et al. [44] 
Collagens I-III Yeast Pichia pastoris 200~600 mg/L depending 
on the collagen type 
Myllyharju et al. [8]  
Collagen I α1 Yeast Pichia pastoris 
(SMD1168/pPIC9K) 
1080 mg/L Li et al. [46] 
Collagen III α1  Yeast Pichia pastoris 
(GS115/pPIC9K) 
1270 mg/L by using the S.  
cerevisiae alpha mating 
factor ( α -MF) 
Wang et al. [47] 
  3360 mg/L (purity 94.6%) Li et al. [48] 
Collagen III  E. coli. BL21 (DE3) 900 mg/L Rutschmann et al. 
[49] 
 
Normally, the level of the protein expression depends on which type of collagen is 
chosen to express and which type of host cell is chosen to use. When using the microbial 
expression system to express the collagen, the condition of the fermentation can also 
play a role. As shown in Table 1, recombinant human collagens express the lowest level 
[40] in insect cells (10 to 20 mg/L), slightly higher in mammalian cells [39], but still 
lower than that in the transgenic tobacco [41], transgenic mouse [43] and transgenic 
silkworm [44]. In general, all mentioned expression systems still need to be improved 
to achieve mass production. Meanwhile, production costs in these processes are 
considerable higher than those in the fermentation process used for other types of cells, 
such as yeast [8, 46-48] or E. coli. [49]. Nevertheless, the yield of the recombinant 
collagen expressed by Yeast Pichia pastoris and the E. coli is significantly higher than 
that by other expression systems. For example, the level of expression achieved in Yeast 
Pichia pastoris can range from 200 to 3360 mg/L [8, 46-48], and 900 mg/L in E. coli 
BL21 (DE3) [49]. Therefore, microbial fermentation seems to be a feasible method to 
achieve a relative mass production. 
 
2.2 Application of recombinant human collagens 
Various recombinant human collagens have been obtained and applied in biomedical 
engineering since they were developed [7-10]. However, due to the limited mechanical 
strength, they were mainly used in repairing damages in neural, skin, cartilage, 
tendinopathy and cardiac therapy [14-18]. For example, Que et al. [14] introduced the 
full-length human collagen type III genes into CEN/ARS plasmids, the plasmids were 
then transformed into S. cerevisiae strain BYα2β2 to induce type III collagen 
expression. This recombinant collagen was then used as a scaffold for human neural 
stem/progenitor cells. Woodley et al. [15] obtained the recombinant human type VII 
collagen and used it to treat skin wounds such as dystrophic epidermolysis bullosa. 
James et al. [16] developed the recombinant human collagen type I and type III 
injectable hydrogels and used them for cardiac therapy. As such, several different types 
of recombinant human collagens were developed and used in repair and reconstruction 
of tissue [35]. For example, the recombinant collagen type III has been widely studied 
in tissue engineering as collagen type III is mainly found in infant skin, intima, or 
intestine. The recombinant collagen type VII is increasingly being used for skin disease 
treatment due to collagen type VII being mainly found in healthy skin. Collagen type 
II has been extensively studied in cartilage defect repair [53-55]. The details of the 
applications of the recombinant human collagens in recent years were summarized in 
Table 2. 
 
Table 2. Application of recombinant human collagens 
Recombinant collagen type Application Properties and Effects Ref. Year 
collagen type I and type III For cardiac therapy As scaffolds to support endogenous cells and to promote the 
regeneration of ischemic tissue 
[16]  2017 
collagen type I Treatment of lateral 
epicondylar tendinopathy 
The efficacy of this new treatment is better than others currently 
available injection treatments in chronic lateral epicondylitis  
[17]  2019 
collagen type II Cartilage tissue engineering Chondrocytes retained their round shape, proliferated, and 
produced an extracellular matrix typical of articular cartilage 
when grown in the recombinant human type II collagen gels.  
[53]  2008 
collagen type II Cartilage in nude mouse 
model 
Recombinant human type II collagen gel as a scaffold for 
chondrocytes promoted a better maintenance of neotissue 
construct shape, compared with the cells without a scaffold. The 
soft gel material without any synthetic or animal-derived additives 
allows a safe and reproducible way of adding more structural 
competence to the implantation of chondrocytes.  
[54]  2010 
collagen type II Providing 3D micro-
environment for 
chondrogenesis of human 
bone marrow-derived 
mesenchymal stromal cells 
(BM-MSCs) 
Recombinant human type II collagen hydrogel induces a transient, 
reversible catabolic disturbance in the chondrogenic 
differentiation of BM-MSCs, a process potentially beneficial in 
graft integration. This study further adds evidence on the role of 
3D scaffolds as bioactive micro-environments and modulators of 
tissue reorganization, with important implications for cartilage 
tissue engineering. 
[55]  2015 
collagen type III Corneal regeneration This biosynthetic implant promoted endogenous regeneration of 
corneal tissue and nerves that were stable over four years, without 
any rejection episodes and in the absence of immunosuppression. 
In terms of aesthetic appearance, resolution of the initial blinding 
pathology and potential for restoration of vision in the long term.  
[56]  2014 
collagen type III Corneal substitute The structure of the biosynthetic hydrogels differs substantially 
from the human cornea, but both have a high transparency to 
visible light. The transparency of the hydrogel may be attributed 
primarily to its high-water content and narrow collagen filaments. 
Patients implanted with these hydrogels should exercise caution 
regarding UV exposure, particularly in the period prior to 
epithelial regrowth.  
[57]  2015 
collagen type III As substitutes for the 
corneal extracellular matrix  
Promote endogenous regeneration of corneal tissue [18]  2015 
collagen type III As a scaffold for human 
neural stem/progenitor cells 
These recombinant collagens can form hydrogel as a cell delivery 
scaffold and support differentiation of hNSPCs into neurons and 
astrocytes.   
[14]  2018 
collagen type VII To treat skin wounds such 
as recessive dystrophic 
epidermolysis bullosa 
(RDEB) 
The collagens can simultaneously migrate to the dermal epidermal 
junction (DEJ) throughout the RDEB patient’s skin, reverse the 
‘subclinical’, microscopic epidermal-dermal separation and 
prophylactically prevent frank skin blisters and erosions from 
forming.  
[15]  2013 
collagen type VII To treat RDEB Human mesenchymal stromal cells engineered to express collagen 
VII in skin graft chimeras to treat RDEB 
[58]  2019 
collagen type 7A1 Gene-corrected fibroblast 
therapy for RDEB using a 
self-inactivating COL7A1 
retroviral vector 
The efficacy and safety of gene-corrected fibroblast therapy using 
a self-inactivating vector that has now been good manufacturing 
grade-certified and pave the way for clinical translation to treat 
non-healing wounds in RDEB patients.  
[59]  2016 
collagen type 7A1 Ex vivo COL7A1 
correction for RDEB using 
CRISPR/Cas9 and 
homology-directed repair  
Precise genome editing in primary RDEB cells is a relevant 
strategy to genetically correct COL7A1 mutations 
[60]  2018 
 
 
2.3 Challenges for the application of recombinant human collagens 
All applications of recombinant human collagens are mainly based on the type of 
collagen used and rely on the properties of related tissue structure on which collagens 
are applied to. Although an improved efficacy and effect is achieved, the systematical 
use of recombinant human collagens still face lots of challenges in both producing 
recombinant human colleagues itself such as a low-yield and high production cost due 
to recombinant human collagens lacking of stability and quick degrading during the 
purification process, and in introducing new methods and techniques to produce new 
structure of collagens with enhanced properties. Due to these reasons, their applications 
are still limited, especially in clinical environments. Most applications of the 
recombinant human collagens remain on animal studies. 
 
However, there are still some excitements of some recombinant human collagens 
having been utilized in the clinics [17]. For example, recombinant human type I 
collagen has been applied for the treatment of lateral epicondylar tendinopathy (tennis 
elbow) and achieved a successful efficacy [17]. Another example is that FDA approved 
collagen type I nerve conduits have been implemented for defects smaller than 3 cm in 
clinic conditions [61, 62]. However, the recombinant human type I collagen have not 
widely applied in the neuron outgrowth and enhance Schwann cell proliferation and 
extension due to the low expression level of recombinant human type I collagen in the 
host cells. There are also some controversial examples of its application. For example, 
in 2019 there was a report that human mesenchymal stromal cells engineered to express 
collagen VII can restore anchoring fibrils in the skin graft chimeras to treat patients 
with recessive dystrophic epidermolysis bullosa (RDEB). But actually it is unlikely that 
recombinant collagen VII could be delivered to the dermal-epidermal basement 
membrane, processed by C proteinase, and assembled into anchoring fibrils. 
Furthermore, RDEB patients frequently do not produce collagen VII. Thus, injecting 
the recombinant version of this protein could lead to the production of antibodies and 
cause consequences similar to those seen in patients with epidermolysis bullosa (EB). 
 
One of the fundamental properties of native collagens is their ability to assemble into 
specific structures, including fibrils, networks, and other. But there are reported 
examples of recombinant mutated collagens, e.g. collagen II, that lose their ability to 
form fibrillar structures [54]. The reasons for this are not fully understood. As most of 
the cell-collagen interactions depend on the binding of specific receptors with unique 
domains present within collagenous assemblies, the lack of ability to form 
supramolecular assemblies presents a potentially significant problem. 
 
In addition, the recombinant collagen technology itself faces economic challenge to 
mass produce the recombinant collagen needed. The complicated production procedure 
and the cost of implementing it normally overtook the cost of products that utilize native 
collagens from animal sources. 
 
Therefore, new approach is desperately needed to fundamentally to change, to improve 
and to extend the applications of recombinant human collagens. There are several 
factors which could be considered: (i) developing various recombinant collagens to 
meet the need of different tissue applications, (ii) using more expression systems to 
improve the expression level of recombinant collage, (iii) modifying the structure of 
recombinant collagen to obtain better properties for different purpose in applications, 
such as using linkers to link with other materials to improve its mechanical strength, 
(iv) combing with new genetic modification and biochemical methods to produce new 
structure of recombinant collage with enhanced properties. 
 
3. Recombinant human-like collagen 
Based on the human collagen repeat peptide sequence (Gly-Xaa-Yaa)n (where Xaa and 
Yaa represents one random amino acid), the collagen sequence template can be 
modified through changing the Xaa and Yaa of the (Gly-Xaa-Yaa)n sequence into any 
amino acid [22-24]. Using this modified collagen sequence as the backbone, novel 
recombinant human collagen can be designed to accommodate different types of 
proteins with different sequences and with different properties. As the backbone gene 
is not a natural human collagen gene code but is a novel sequence from modifying 
several repeat sequences of the human collagen cDNA, this novel modified collagen is 
therefore named as human-like collagen (HLC). There have been several types of HLCs 
produced in this way [11, 19-21, 26-32].  
 
Different from the traditional recombinant human collagens, the cDNA of the human 
collagens can be modified within the HLCs, such as changing the Xaa and Yaa in the 
repeat peptide (Gly-Xaa-Yaa)n sequence to adjust the pI, the number of lysines, cell 
binding domain, etc. of the HLC. Therefore, the HLCs are more stable, degrade slowly 
and thus easier to purify [20, 26-32]. The yield of the HLC is also significantly higher 
than that of traditional recombinant human collagen. Additionally, more lysines added 
to the HLC sequence template promotes the cells adhesion [11, 26, 28], this 
consequently enhances the application of HLCs in the treatment of different injured 
tissues [11, 26, 28]. Normally the human-like collagen requires chemical cross-linking 
or mixing with other materials to improve mechanical integrity as do many other 
collagens. The unique properties of HLC contain more -NH2 which make it much easier 
to cross-link and mix with other materials [28]. Therefore, this novel recombinant 
human collagen (HLC) can achieve improved stability, higher yield, slower 
biodegradation speed and better cell adhesion. 
 
Due to its excellent biocompatibility, low immunogenicity, the stabilised property and 
mass production ability, the HLC has been successfully used in tissue engineering to 
repair organ tissue damage based on animal models and received growing extensive 
attention [63-65]. The following sections will focus on discussing how to express and 
purify the recombinant HLCs and how to facilitate them in biomedical and clinical 
applications. 
 
3.1 Expression of recombinant human-like collagen 
Designing and modifying several repeat sequences of the human collagen cDNA and 
choosing suitable expression system proves to be very challenging. Optimising a best 
fermentation condition is the practical endeavor for the success of obtaining HLC 




Figure 1. The standard procedure for producing the HLCs 
 
Apart from three recent reports [66-69] of successful expression of HLCs, we are the 
only group which successfully express and produce the HLCs (Table 3). 
 
Table 3. Recombinant human-like collagen 
Host Yield  MW. Ref. 
E. coli. origami (DE3) 260 mg/L in a 10 L fermentor 35 kDa Tang et al. [66] 
E. coli. Rosetta (DE3) Shake flask culture 40 kDa Yang et al. [67] 
E. coli. BL21 (DE3) Shake flask culture 37 kDa Peng et al. [68, 69]  
E. coli. BL21 (DE3) 14 g/L in a 500 L fermentor 93 kDa Fan et al. [19, 30] 
 
In Tang et al.’s study [66], the HLC gene, human prolyl 4-hydroxylase and D-
arabinono-1, 4-lactone oxidase were co-expressed in E. coli. origami (DE3) to produce 
the hydroxylated HLC (approximate 35 kDa). The yield was up to 260 mg/L in a 10 L 
fermentor. In Yang et al.’s study [67], human-like type I collagen was expressed using 
Escherichia coli Rosetta (DE3) and had approximate 40 kDa molecular weight. In Peng 
et al.’s [61, 62] study, HLC was expressed using E. coli. BL21 (DE3) and had 
approximate 37 kDa molecular weight. While in Fan et al.’ lab, the HLC (93 kDa) 
expressing recombinant E. coli BL21 (DE3) was constructed using a plasmid with 
kanamycin resistance and temperature induction genes [19, 30]. A stabilised high-yield 
HLCs production is routinely achieved. This level of expression, around 14g/L in 500 
L fermentor is significantly higher than that of the above producer and the full-length 
human collagen (900 mg/L, Table 1).  
 
Apart from the differences in host E. coli, the expression of HLC in Yang et al. [67] and 
Peng et al. [68, 69] was purely through shaking flask culture; and the yield of HLC in 
Tang et al. [66] was 260 mg/L using a 10 L fermentor. Notably, the yield of HLC in Fan 
et al. [19, 30] reached 14 g/L in a 500 L fermentor.  
 
As it is expected that normally the technological requirement for recombinant collagens 
is high and there is a large amount of initial investment required to be able to start with. 
There are also lots of technical barriers need to be overcome before final mass 
production can be achieved, such as constructing the recombinant plasmid, obtaining 
engineered host cells to express mass target collagens, monitoring high-density 
fermentation and purification of the collagens etc. Initial setting up and producing 
reasonable amount of recombinant human collagens to use even on the animal 
experiments costed more than those of using animal-derived collagens directly. This is 
probably reason for the delayed broadcasting of this new technology. However, the 
advantages of the recombinant human collagens in better biocompatibility and lower 
immunogenicity is much better than those of native collagens from animal sources and 
attracted scientists to continuously develop this technology. Considering all the benefits 
and its cost-efficient in the production process, human-like collagen if successful 
certainly has great advantage than its animal extracted counterparts.    
 
The reasons for the success of the high level of the HLC product in Fan et al.’lab are 
due to the following key considerations: (i) Choosing the right expression system, E. 
coli BL21 (DE3); (ii) Designing a suitable molecular weight of 93 kDa; (iii) Optimising 
a best fermentation condition. According to the metabolism characteristics of E. coli, a 
variety of regulatory strategies for HLC production were performed in our laboratory. 
For example, the high-density fermentation of recombinant E. coli. had been studied, 
including the effects of different oxygen control methods, nitrogen supplementation 
methods and different induction conditions on bacterial growth and HLC expression. 
Meanwhile, the kinetic and metabolic pathway fluxes of the bacterial growth and HLC 
expression were analysed in Fan et al.’s previous studies. Presently, Fan et al. have 
promoted the level of HLC expression to around 14g/L in 500 L fermentor, and the 
HLC with further properties such as additional stabilization, slow degradation, easily 
purification [70].  
As a consequence , sufficient supplement of HLC is available and make it possible for  
us to explore its various applications, including skin injury treatments [71-76], vascular 
scaffolds engineering [77-80], cartilage [81, 82] and bone defect repair [83-90], and 
haemostatic sponge [28, 91, 92] etc.  
 
3.2 Potential application of the human-like collagen in tissue engineering 
In early studies, the HLC was not able to be used alone but as a coating to the scaffold 
due to its poor mechanical strength. For example, HLCs are usually used to coat or mix 
with the calcium phosphate ceramics, metals, or polymers to improve the compatibility 
and remain the stiffness of the substrate scaffold [79, 80, 82, 87, 88]. In order to increase 
the strength of the HLC to meet the requirement of the scaffold, compatible cross-link 
agents were used. For example, HLC was cross-linked by the dialdehyde starch (DAS) 
[71], oleuropein [89], 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) [93, 94], 
EDC and adipic acid dihydrazide (ADH) [95], 1,4-butanediol diglycidyl ether (BDDE) 
[96-98], β-sodium glycerophosphate (β-GP) [99-101], and transglutaminase (TG) [11]. 
Cross-linked HLCs are in general mechanically strong and stable and therefore become 
the most popular scaffold option. Among them, the HLC cross-linked by TG is the most 
strong and stable, its mechanism and the chemical reaction is shown in Figure 2a. The 
wet HLC hydrogel obtained (Figure 2b) can achieve excellent flexiblity and water 
absorption capacity, and therefore can be made into various shapes to meet the different 
needs in the clinical transplantations. 
 
                   
Figure 2. The cross-linked HLC hydrogel [11] (a) The mechanism and the chemical 
reaction of the HLC hydrogel cross-linked by TG. (b) The morphology of the HLC 
hydrogel. 
 
In the following sections, we summarised the main applications of HLC in tissue 
engineering. Although most of the applications were studied on animal models, they 
presented the great potential for biomedical and clinical applications. The HLC used in 
all these applications is fundamentally the same. By choosing different cross-linkers 
and using different methods to link with HLC, the structure feature and performance of 
HLC are greatly improved with additional properties to fit for the intended applications. 
All the HLC sequence used in our studies can be required directly to us for research 
purpose. 
3.2.1 Skin repair and skin regeneration 
HLCs have been researched extensively on injured skin repair and skin regeneration 
due to their biocompatibility since it first produced. As early as 2014, Ma et al. mixed 
HLC with chitosan, cross-linked them by dialdehyde starch [71], and obtained a soft 
biocompatible hydrogel. This soft hydrogel can effectively fill dermal voids with little 
or no inflammatory responses.  
 
In 2016, Zhao et al. created an injectable HLC hydrogel cross-linked by microbial 
transglutaminase for skin regeneration [72]. Cross-linking microbial transglutaminase 
(MTGase, 40U/g of HLC), a nontoxic crosslinker with high specific activity and 
reaction rate under mild condition, improved the biocompatibility of the HLC hydrogel. 
In addition, compared with the commercial collagen (Collagen Implant I®, SUM) [72], 
this new injectable HLC hydrogel had a lower toxicity and better biocompatibility in 
animal experiments, and thus showed great potential as an injectable hydrogel applied 
in skin injury treatment.  
 
In 2018, Zhu et al. [73] used the transglutaminase (TG) to cross-link the hyaluronic 
acid, carboxylated chitosan (CCS) and HLC. In vivo experiments on the rabbit skin 
defect model showed the hydrogels obtained in this way had powerful strength (Figure 
3), could protect the wound from infection and fluid loss, and therefore effectively 
promote wound healing. 
        
Figure 3. TG cross-linked HLC hydrogels were used in rabbit skin wound healing 
[73]. (a) Tensile stress-strain curves of the hydrogels; (b) Cyclic compressive 
mechanical tests. 
 
In 2019, Guo et al. [74] developed a TG cross-linked HLC hydrogel loaded with basic 
fibroblast growth factor (b-FGF) to repair the defect skin. In vivo findings showed that 
the b-FGF -containing HLC/TG hydrogel can dramatically promote the healing of 
defect skin and achieve scar less healing in a shorter time. Therefore, this hydrogel 
provided a safe, moist environment, and fully enhanced roles of b-FGF and HLC/TG 
hydrogel to promote wound healing. TG cross-linked HLC hydrogels have the 
advantage of mild reaction conditions which make it possible to be a growth factor and 
cell’s carrier and to be implanted. Most importantly, TG cross-linked HLC hydrogel 
promotes wound healing without causing side effects. Thus, it provides significant 
potential for clinical use. 
 
Recently, Pan et al. designed breathable haemostatic HLC-based hydrogel dressings 
and determined their effects on full-thickness defects [75, 76]. Initially, they fabricated 
a series of soft, flexible, porous non-stick hydrogel dressings through the repeated 
freeze-thawing of a mixed solution of poly(vinylalcohol) (PVA) and HLC with/without 
adding with carboxymethyl chitosan and then Tween80 was added as pore-forming 
agent for cutaneous wound healing (Figure 4a, b) [75]. The combined effects of various 
functions of the two hydrogels obviously promoted full-thickness skin wound healing 
when compared to the commercial dressing (Figure 4c). In 2019, they fabricated 
another novel HLC, PVA and sodium alginate (SA) composite hydrogel as wound 
dressings (Figure 4e-h) [76]. Their results showed that the hydrogel can accelerate 
wound contraction in full-thickness wounds of rabbits, promote wound healing and new 
skin formation, demonstrating its great potential as a wound dressing for skin wound 
healing (Figure 4d). 
 
In summary, HLCs have great biocompatibility and when aided with proper cross-
linkers it can be successfully used on injured skin repair and skin regeneration. In fact, 
Fan et al.’s lab [71-76] has been collaborating with hospitals to start clinical trials of 
using HLC dressing for skin repair and skin regeneration. There are also some cosmetic 
products of HLC to be put on the market. 
 
   
Figure 4. HLC-based hydrogel and its effects on full-thickness skin defects [75, 76]. 
(a) The formation process of PVA-HLC-T80 ①  Solution blending process ② 
Addition of Tween80 ③  Repeated freeze-thawing process ④  The process of 
removing Tween80; (b) The hydrogels with Tween80 kept soft after lyophilization; (c) 
The wound after different time intervals; Morphology of the PVA-HLC-SA hydrogel 
(e) The hydrogel (f) Lyophilized hydrogel (g) Kept soft after lyophilized (h) SEM 
images; (d) The wound after different time intervals. PVA: Poly (vinyl alcohol). HLC: 
Human-like collagen. CS: Chitosan. T80: Tween80. SA: Sodium alginate. 
 
3.2.2 Vascular scaffolds engineering  
Series studies since 2009 show that the HLC is an ideal “raw” material on which 
vascular scaffolds can be fabricated through cross-linking with appropriate materials 
and by different cross-linking methods [77-78]. This therefore provides great potential 
for HLC to be used in vascular scaffolds engineering. 
 
As early as 2009, the blood vessel tubular grafts were fabricated by cross-link HLC and 
hyaluronic acid (HA) with genipin and through the freeze-drying method [77]. This 
HLC-HA tubular graft had interconnected, well-distributed porous structure, and the 
porosity reached 94.38%. It also achieved the desirable stress and burst press properties 
for application standard.  
 
In 2014, Zhu et al. [79] investigated the strength variation of the HLC-HA scaffolds 
using different blending rate of the HLC and HA. They found that the ratio of 10 HLC 
to 1 HA was an optimal choice. The scaffolds obtained have advantageous properties 
such as the interconnected porous structure (Figure 5), high porosity (89.3%), better 
mechanical properties (stress of 321.7±15kPa and strain of 45.5±0.2%), less 
degradation rate (9%), and excellent biocompatibility. All of the above make it a broad 
prospective candidate for a blood vessel tubular graft. 
 
     
Figure 5. HLC-hyaluronic acid tubular vascular scaffolds [79] (a) Gross observation 
and (b,c) SEM imagines of the scaffolds. 
 
In addition to using the freeze-drying method, Zhu et al. [80] attempted to construct the 
vascular tissue scaffold using co-electrospun of HLC/CS/PLA (human-like collagen/ 
chitosan/ poly lactic-acid). The use of PLA could improve the strength of the scaffold, 
and the CS and HLC could supply a more biomimetic structure and better 
hemocompatibility.  
 
The natural blood vessel wall is flexible, and one of the main ECM in the vessel is 
collagen. The recombinant HLC and modified HLC scaffolds have the similar 
components and properties of the natural blood vessel wall. This makes it an ideal 
material for developing vascular regeneration. 
 
3.2.3 Cartilage tissue engineering 
Collagen is a main extracellular matrix protein in the cartilage, and the recombinant 
HLC is therefore appropriate for application in cartilage tissue engineering. However, 
the mechanical strength of the HLC cannot meet that of cartilage. Therefore 
hydroxyapatite (HA) is usually added into the HLC to form a complex scaffold in order 
to meet the requirement of the mechanical strength. 
 
For example, in 2013, Jia et al. [81] used the HLC as basic materials, and mixed nano-
hydroxyapatite (nHA) to fabricate a HLC/nHA composite scaffold with homogeneous 
and interconnected porous structure. This scaffold can withstand a higher compression 
stress (2.67 ± 0.37 MPa) than that of the Relive® Artificial Bone (RAB) scaffolds [81], 
and is beneficial to rabbit chondrocytes adhesion, glycosaminoglycan synthesis, and 
chondrocyte morphology maintaining (Figure 6a-d). Simultaneously, Fan et al. [82] 
also found that the HLC/nHA scaffolds had excellent cytocompatibility and could 
maintain chondrocyte spherical morphology.  
 
All the above in vitro data warranted the HLC/nHA scaffold as a potential biomimetic 
platform for chondrocytes in cartilage tissue engineering. But in vivo verification is still 
needed as the HA cannot degrade in vivo, which may cause problems. 
 
In 2017, Song et al. [11] prepared an HLC only hydrogel scaffold with unique porous 
structure and used it in rabbit articular cartilage defect repair. 12 weeks post 
implantation of the HLC scaffolds, the defect in the control group (none of implant) 
was not recovered (Figure 6e, g), but the defect in the HLC treated group returned to 
normal (Figure 6f, h). These results further support that the HLC hydrogel scaffold can 
encourage cartilage repair. 
 
  
Figure 6. HLC as raw materials applied in cartilage tissue engineering. (a-d) were 
the in vitro experiment results of the HLC/nHA scaffold [81]. (e-h) were the in vivo 
experiment results of the HLC scaffold [11]. Chondrocytes on (a) HLC/nHA scaffold, 
(b) RAB scaffold for 7 days and (c) HLC/nHA scaffold, (d) RAB scaffold for 21 days 
by SEM. (e, f) were macroscopic images of the cartilage joint 12 weeks after surgery: 
(e) The control group; (f) The HLC group. (g, h) were histological analysis of the 
cartilage defect area 12 weeks after surgery: The control group (g) and the HLC group 
(h) stained with H&E. 
 
Improving the mechanical strength of HLCs is the key for it to be used in cartilage 
tissue engineering. Choosing suitable materials to meet the requirement of stiffness for 
the cartilage tissue engineering scaffold is continuous efforts to pursue. This principle 
also applies to other applications of HLC as well. 
 
3.2.4 Bone defect repair 
HLC can be used to repair not only skin, vascular and cartilage tissue damage, but also 
bone tissue damage. When HLC is combined with natural materials, synthetic materials 
or nanomaterials, its mechanical strength can be greatly enhanced, and its 
biodegradation can also be controlled so that they can be used in the bone defect repair.  
 
There are many publications based on HLC added with tough component and used in 
bone repairing. Calcium phosphate ceramics, metals, or synthetic polymers, such as HA, 
Ti, NiTi alloy and PLA are usually used to composite scaffolds for bone defect repair 
[83-90]. For example, NiTi shape memory alloy was used as the basic scaffold. The 
HLC was then used to modify the surface of the NiTi so as to better biofunctionalise 
the alloy [87]. The HLC coating benefits the application of NiTi alloy in the orthopaedic 
field. Li et al. [88] further investigated the effect of osteogenesis of the titanium scaffold 
with HA and HLC coating. Compared with the HA surface layer, the HA/HLC surface 
layer could promote the survival of the osteoblasts. Notably, the varied concentrations 
and the methods of HLC addition could all significantly improve the survival rate of 
the osteoblasts. Therefore, HLC molecules could homogeneously distribute on the HA-
coated titanium scaffold and provide a favourable position for the osteoblasts. 
 
Although metal materials such as Ti and NiTi alloy can supply the “hard scaffold” for 
the bone repair, they will not degrade and will exist in the host for a lifetime once 
implanted. In order to avoid the foreign body implantation, Fan et al. tried to fabricate 
a porous composite scaffold with HLC and nHA through cross-linking by oleuropein 
for bone tissue engineering [89]. When adding the oleuropein solution (2% w/v) to 
cross-link the HLC and nHA, the compressive strength and Young’s modulus of the 
scaffold reached maximums of 2.97 ± 0.19 MPa and 43.03 ± 6.17 MPa, respectively.  
Due to the success of the HLC/nHA applied in bone tissue engineering [89], in 2017, 
Zhou et al. [83] fabricated the 3D porous scaffold based on HLC, nHA, biodegradable 
polylactic acid, and polydopamine (pDA)-assisted BMP-2-derived peptide 
(nHA/HLC/PLA-pDA-P24). This designed HLC complex scaffold has the stronger 
mechanical strength, controllable biodegradation rate, and could significantly enhance 
bone regeneration of the rat cranial defects. The results indicated that the novel 
nHA/RHLC/PLA-pDA-P24 scaffold was helpful for bone tissue regeneration. 
 
In contrast to the above studies using traditional materials mixing with HLC to promote 
the mechanical strength and make biodegradation rate controllable, Chen et al. recently 
found that HLCs can specially combine with an osteoinductive agent (BMP-2) to 
induce bone regeneration rapidly [90]. Due to the special high binding affinity between 
HLC sponge and BMP-2, the HLC sponge can load with tiny BMP-2 of 1 µg enables 
complete repair of large areas of rat defective bone within 4 weeks. When the HLC-
BMP implant is loaded with 5 µg BMP-2, it can introduce serious bone overgrowth 
which indicates that HLC seems to have an ability to “magnify” and “distinguish” the 
tiny changes of dose of BMP-2 used for maintaining osteoinduction and bone formation 
(Figure 7). 
      
Figure 7. Micro-CT and fluorescent microscopy analysis of the rat cranial defect 
repair using different dose of BMP-2 at 8 weeks after implantation [90]. (a) 
Representative micro-CT images and immunofluorescent staining of implants (Control, 
HLC-BMP sponge loading with 1 µg and 5 µg rhBMP-2 dimer respectively) 8 weeks 
after implantation. Nuclei were stained blue with DAPI, OPN was stained green and 
Runx-2 was stained red. (b) Quantitative estimation of OPN and Runx-2 expression in 
each group (**p < 0.01, ***p < 0.001, n=18). (c) The raw data of Micro-CT of the rat 
cranial defect repair using 1 µg and 5μg dose of rhBMP-2 at 8 weeks after implantation. 
The detailed picture shows that the 1 µg HLC-BMP implant was safe, and that the 
percentage of repair was up to 88.13 ± 6.01 %. However, 5 µg HLC-BMP implant 
introduced serious bone overgrowth. 
 
 
The above results showed that the HLCs could potentially not only be applied in bone 
tissue engineering but could also be developed into a customisable delivery system for 
other growth factors. Therefore, it will be extremely valuable for any defect repair and 
tissue regeneration in both research and clinical applications. We have summarised all 
these studies in below Table 4. Using different crosslink materials to produce a unique 
structure along with other growth factor make the HLC extremely valuable in tissue 
engineering. Continuously optimising the material design to produce more “powerful” 
HLC will certainly expand its applications in tissue engineering.   
   
Table 4. Application of human-like collagen in Tissue engineering 
Materials design Application Properties and Effects Ref. Year 
Microbial transglutaminase - 
crosslinked HLC hydrogels 
Skin tissue 
engineering 
A lower toxicity and better biocompatibility compared with the commercial 
collagen (Collagen Implant I®, SUM)  
[72] 2016 
TG cross-linked HLC 
hydrogel loaded with b-FGF 
Repair the defect 
skin 
This hydrogel can dramatically promote the healing of defect skin and 
achieve scar less healing in a shorter time.  
 
[74] 2019 
HLC with hyaluronic acid 
cross-linked by genipin 
Blood vessel 
tubular grafts 
Interconnected and well-distributed porous structure; porosity of 94.38%; 
high stress of 1000.8 ± 7.9kPa and burst pressure of 1058.6 ± 8.2kPa; 




Intima layer for 
endothelialisation 
of a vascular 
scaffold  
Interconnected porous network and porosity of 89.3%; high stress of 
321.7±15kPa and strain of 45.5±0.2 %; only 9% degradation upon 






Homogeneous interconnected structure with withstand of a compression 
stress of 2.67 ± 0.37 MPa, which was higher than that of Relive® Artificial 
Bone Scaffolds. encouraged chondrocytes cell adhesion, 
glycosaminoglycan synthesis by the HLC/nHA scaffolds and maintained 
natural chondrocyte morphology maintaining  
[81] 2013 




Effectively repairing rabbit articular cartilage damage with nearly 100% 
repairing of the defect in the HLC group and only a blurred boundary 






Significantly enhanced bone regeneration of the rat cranial defects by the 
nHA/HLC/PLA-pDA-P24 scaffolds  
[83] 2017 
HLC directed growth of 
hydroxyapatite nanocrystals 
Bone repair The artificial analog of bone fabricated by the collagen fibrils and the HA 






HLC modulated the growth 
of nHA on NiTi alloy 
Orthopedic field Beneficial application of NiTi alloy in the orthopedic field by the HLC and 
nHA coating with special structure 
[87] 2009 






Significantly promoted survival of the osteoblasts by the HA/HLC surface 
layer compared with the HA surface layer 
[88] 2015 
HLC and BMP-2 complex A large area of 
defective bone 
repair 
HLC sponge loaded with tiny BMP-2 of 1 µg, with profiles of a controlled 
release characterized by a short burst and a steady slow process. self-
Osteogenesis in situ consequently facilitated with the ability of complete 
repair of large areas of defective bone  
[90] 2019 
 
3.2.5 Injectable human-like collagen used in tissue engineering 
Another unique property of the HLC is its injectable. The HLC hydrogel in a syringe 
can be injected through a needle into any shape of the mold. Therefore, injectable HLC 
hydrogel can be used in the tissue filling and repairing. After adding crosslinkers, the 
shape and flexibility of the HLCs could also be changed by different conditions such as 
different pH and temperature for specific use.  
 
For example, HLC and hyaluronic acid (HA) can be crosslinked with 1,4-butanediol 
diglycidyl ether (BDDE) to form an injectable HLC/HA hydrogel [96]. Another 
example of multifunctionalised injectable hydrogel was designed based on HLC and 
high molecular-weight pullulan [97]. Pullulan hydrogel can be formed through cross-
linking by NaIO4, and then coupled with HLC by the reaction between the-NH2 end-
group of HLC and the -CHO group present on the aldehyde pullulan to form the 
injectable HLC/pullulan hydrogel [102]. This injectable HLC/pullulan hydrogel was a 
safe, soft and suitable option for skin restoration, cartilage treatment, and lacrimal 
dryness therapy [97, 102]. 
 
Li et al. [99] designed a novel injectable pH/temperature sensitive chitosan-HLC/β-
sodium glycerophosphate (CS-HLC /β -GP) hydrogel. Through controlling the pH and 
temperature, the shape and properties of the HLCs based hydrogel can be controlled at 
different conditions. For example, the HLC mixture was in solution when the 
environment temperature was lower than body temperature while it would become 
hydrogel at the body temperature [99].  
 
Furthermore, in order to improve the sensitivity and the strength of the CS-HLC-β -GP 
hydrogel, Li et al. added the hyaluronic acid and prepared the chitosan-HLC-hyaluronic 
acid-β-sodium glycerophosphate (CS-HLC-HA-β-GP) hydrogel [100, 101] with a new 
amide bond (-CONH) and -NRH2+. This new hydrogel can change the gelling time and 
swelling behaviors which are dependent on the intertwining, overlap and adsorption of 
the polymer chains at various temperatures and pH [100]. It also has a higher sensitivity 
than the CS-HLC-β -GP hydrogel and exhibits more adequate mechanical strength (1.5-
2 MPa) and crosslinking densities (2.5-4.5×10-3 mol/cm3). Therefore, this new hydrogel 
is more suitable in tissue defect filling.  
 
Due to its sensitivity to pH and temperature changes, flexibility and plasticity, this 
hydrogel can also be easily used as an injectable filling biomaterial in plastic and 
reconstruction surgery, and drug delivery.  
 
3.3 Human-like collagen-based hemostatic sponge 
Using gradient freeze-drying method [103], HLCs can be processed to be sponges. Like 
the commercial collagen sponge, the HLC sponge can be used in the operation of the 
neurosurgery, orthopedics, gynecology, general surgery, operating room, and so on. The 
HLC sponge using as a filler can stop the bleeding rapidly, prevent wound adhesion, 
accelerate wound healing, and reduce the postoperative complications. The effects of 
the HLC haemostatic sponges have been intensively studied in the last decade [28, 91, 
92], the representative studies were summarised as below. 
 
As early as 2007, Mao et al. [91] investigated the haemostatic effect and 
histocompatibility of the chitosan-HLC on 1cm×1cm area of the wound surface of the 
liver of rabbits. In their study, bleeding time and histocompatibility were compared 
among Chitosan-HLC, HLC and gelatin sponges. Their results showed that the 
chitosan-HLC produced a shorter and visibly different bleeding time (78s ± 11s) from 
the gelatin sponge (115s ± 13s, p < 0.05). Histocompatibility of the chitosan-HLC was 
also noticeably better than the gelatin sponge.  
 
In 2014, Meng et al. [92] used SD rats with liver haemorrhage model for comparative 
bleeding tests in order to investigate the haemostatic effect and histocompatibility of 
HLC. Blooding time (94 ± 13s) with HLC sponge was significantly shorter than that 
(121 ± 15s) with the purchased microporous starch (used as the control). This result 
showed that the HLC sponge had a positive effect on the haemostatic area.  
 
In 2017, Jiang et al. [28] prepared a novel haemostatic sponge using HLC and 
glutamine transaminase (non-toxic cross-linker) via "two-step" freezing. The HLC 
sponge showed a uniform morphology, good biodegradability, and good 
biocompatibility in implantation tests and had a well haemostatic effect in the ear artery 
and liver injury models.  
 
In addition, due to its high efficient biodegradability and easily digested though 
metabolism, the HLC sponge can facilitate seamless healing in the above injury models 
[28].  
 
The above applications are typical example of the successful application of HLC. To 
achieve further various applications, modifying HLC with aided cross-linkers to obtain 
enhance properties will be the main efforts to focus on. With more developments in 
materials sciences, more new productions are to be expected.   
 
3.4 Human-like collagen used in clinic for skincare 
Diversely from being used in the dermis injury repair, HLC has been widely used in 
epidermis-care which contains promotion of skin elasticity, skin moisture, shrink pores, 
and so on [104]. In general, the HLCs can be directly daubed on the skin to protect the 
epidermis. Additionally, the HLCs can also be absorbed in non-woven fabrics and 
formed the HLC dressing. 
 
For example, Chen et al. [104] investigated the effect of infrared rays combined with 
HLC dressing to improve skin quality after photoaging with lattice CO2 laser. In their 
study, pigment spots, wrinkles, texture, pores, moisture, elasticity and rhodopsin scores 
from the treatment with infrared ray combined with HLC dressing were significantly 
better than that with infrared ray alone. This suggested that HLC dressing can improve 
the quality of infrared ray treatment on the skin and thus provides a new method and a 
novelty agent for skincare. 
 
The HLC dressings can also be used as a drug delivery system and applied in the 
treatment of skin diseases. For example, HLC dressings were used to slow-release a 
traditional Chinese medicine (Biantong Baihu decoction) to treat facial contact 
dermatitis [105]. The efficiency rate of Biantong Baihu decoction combined with the 
HLC dressings reached 87.88%, much higher than that of Biantong Baihu decoction 
alone. Therefore, HLC dressings can efficiently deliver Biantong Baihu decoction and 
has significant clinical efficacy on facial contact dermatitis [105]. 
 
Because the recombinant HLC is biocompatible and similar to natural collagen in the 
body, there is no allergic contact reaction for patients with sensitive skin. We have 
developed a skin care product, HLCs (COLLGENE®) and have been successfully used 
in clinic for cosmetic skin care for nearly 16 years.  
 
3.5 Potential application of Human-like collagen in other diseases treatment 
Because the HLC is an edible and biodegradable protein, it can therefore be used to 
encapsulate oral medicines [106, 107]. The biodegradable HLC is suitable for 
encapsulation of the intestinal probiotics, which could protect the probiotics from the 
gastric environment and release the probiotics effectively in the intestinal tract.  
 
For example, Su et al. [108] encapsulated the probiotic Bifidobacterium longum 
BIOMA 5920 using alginate-HLC (ALg-HLC) and evaluated the B. longum survival 
in simulated gastrointestinal conditions. Compared with ALg microspheres, ALg-HLC 
microspheres could better protect bifidobacteria from the simulated gastric juice (SGJ). 
When the encapsulated B. longum was exposed to simulated intestinal juice (SIJ) of pH 
7.0, HLC was dissolved faster than that of ALg in SIJ, which lead to the treatment 
efficacy of ALg-HLC microspheres being higher than that of ALg microspheres alone 
in intestinal conditions. 
 
Another example is microencapsulation of phosphorylated HLC-calcium chelates 
developed based on the phosphorylated HLC (PHLC) calcium complex [109], to 
control PHLC-Ca delivery and improve their bioavailability [110]. The ALG and CS 
were used as wall materials to protect and control the release of the PHLC-Ca. The 
PHLC-Ca was entrapped into the matrix of ALG through forming intermolecular 
hydrogen bonding or other interactions. Therefore, the bioavailability of the PHLC-Ca 
was improved by CS/ALG. This will stimulate new thoughts for future proteins calcium 
supplements. 
 
Recently, Li et al. [111] fabricated HLC-based hydrogels using microbial 
transglutaminase (MTGase) and the 1-ethyl-3-methylimidazolium acetate ([EMIM] 
[Ac]). They found that the development of this enzymatic hydrogel with controlled 
biodegradation rates can meet the needs of specific potential applications, such as tissue 
engineering and cancer therapy (Figure 8). 
      
Figure 8. Synthetic mechanism and potential applications of HLC-based hydrogels 
by MTGase/[EMIM] [AC] [111]. 
 
 
Further application of HLC is to coat medical nanoparticles for the treatment of disease. 
After coating with the HLCs, the biocompatibility and bioavailability of nanoparticles 
can be improved which in turn greatly improve the efficiency of the medical 
nanoparticles [112-115]. For example, HLC-coated Fe3O4 nanoparticles were 
successfully prepared to test its effect on heat induction and cell toxicity [112, 113]. 
After coating of HLC, even with a reduced saturation, magnetisation temperature can 
increase at a faster rate under an alternating magnetic field. This might be due to the 
effective heat conduction and good colloid stability caused by the high surface charge 
of HLC. In addition, HLC-coated Fe3O4 nanoparticles can induce less cell toxicity at a 
higher concentration. Therefore, the effective heat induction can be achieved for 
example in cancer treatment with improved biocompatibility [112, 113]. 
 
Another example of this application is using the HLC to deliver iron effectively. Low 
iron intake and/or bioavailability cause worldwide iron deficiency. Fe3O4 are rich in 
iron but have poor bioavailability. Zhu et al. [114] used a thiolated HLC to protect the 
Fe3O4 and maintain the iron effectively. They found that the thiolated HLC-iron had 
less cytotoxicity and higher bioavailability than the bare iron. This ensures the thiolated 
HLC-iron as a more effective iron supplement for clinic in the future [114, 115]. 
 
The above examples illustrated the great potential of using HLC as an effective deliver 
system in clinical applications. Mass production ability of HLC would make 
furthermore development possible and surely foresee more applications in the future. 
  
4. Summary 
Both the recombinant sources of human collagen and human-like collagen are reliable, 
predictable and chemically defined source of purified human collagens and they are 
animal-free. However, compared with the recombinant human collagens, the 
recombinant HLC is more stable, degrades slowly, and is easy to purify [20, 26-32]. 
The HLC has good biocompatibility, no immunogenicity, stabilized property and can 
be mass produced. It’s exciting that some HLCs have already been utilized in the clinics. 
However, except applications in hemostatic sponge, skin injury treatments, and skin-
care [104, 105], most of the HLCs applications still remain in the stage of animal testing, 
such as vascular scaffolds engineering [77-80], cartilage [81, 82] and bone defect repair 
[83-90], and other diseases treatment [106-111]. 
 
Using properly chosen cross-linkers, improved properties of HLC could be expected, 
and more biomedical and clinical applications of HLC should be able to be developed 
in the future (Figure 9). 
 
          
Figure 9. Potential applications of the HLCs in biomedicine. Due to its good 
biocompatibility, no immunogenicity, stabilised properties and mass production ability, 
HLC has been widely researched in skin injury treatments, vascular scaffolds 
engineering, cartilage and bone defect repair, haemostatic sponge, skincare, drug 
delivery, coating of medical nanoparticle, etc. 
 
5. Future improvements 
Compared to naturally derive animal collagen which show variation in quality, purity, 
predictability of performance and the risk of transmission of infectious, collagens 
defined recombinant human collagen eliminate disease risk. Additionally, recombinant 
technology allows collagen produced with significant quantities, new and non-native 
structures, including chimeric molecules and novel designed structures. Presently, 
many expression systems have allowed trials on concepts, but few systems have been 
proven to be successful as yet for commercial scale production of new biomaterials 
[116]. Full length recombinant human collagens have been successfully expressed in 
cell lines, yeast, and several plant systems, while collagen fragments have been 
expressed in E. coli. In addition, bacterial collagen-like proteins (e.g. HLC) can be 
expressed in high yields in E. coli and easily manipulated to incorporate biologically 
active sequences from human collagens [117]. Although the yield of HLC in Fan et al. 
[19, 30] has reached 14 g/L in a 500 L fermentor and the HLC has many biomedical 
applications, there are still many aspects which can be improved so that the production 
of HLC can be easier, the quality of HLC can be more qualified, and the designing of 
HLC can be more flexible. With these improvements, the application of HLC will 
become more precise and efficient in each area of biomedical application. Here we have 
focused on some considerations displayed in our laboratory to improve the production 
of HLC as it is the key for the successful application. Without enough high quantity and 
easily made HLC there are limits to its potential applications.  
 
5.1 Optimal use of collagen cross-linker 
HLC need to cross-link with different cross-linkers such as the DAS [71], oleuropein 
[89], EDC [93, 94], EDC and ADH [95], BDDE [96-98], β-GP [99-101], and TG [11]   
to adjust the mechanical properties of the HLC scaffolds. Up to now, TG is one of the 
best cross-linkers for HLCs’ crosslink. TG is an inherent enzyme in the human body, 
which is degradable, biocompatible. Most importantly, TG can work in the mild 
reaction condition (4℃ overnight) that can remain the activity of the protein. However, 
the mechanical strength of the HLC can’t reach the stiffness of bone and cartilage 
simply through the cross-linker. Therefore, optimal use of cross linker with specific 
materials such as BMPs in different environment is the key to meet specific need in 
those applications  [83, 90]. The fast reaction time during the cross-link is another 
future need to be improved. At the present, the time for HLC and the crosslinkers to 
form shape in normal human body environment is too long which greatly limits its 
applications. Therefore, it will be crucially important to develop novel cross-linkers and 
cross-link methods such as those can adapt the environment of human body to extend 
the application of HLCs. 
 
5.2 More choices of expression systems for HLC 
Up to now, the HLCs are expressed by E. coli which belongs to prokaryotic cell. The 
prokaryotic cell may bring the prokaryotic cytoplasm when collecting the HLCs. Some 
of the products from the prokaryotic cell such as bacterial endotoxin is harmful for 
humans [118, 119]. In order to avoid this potential risk, a eukaryotic expression vector 
such as a yeast system needs to be considered to construct and express the HLCs. 
Besides, using yeast expression vectors to express HLCs in the supernatant of the 
fermented medium this could make HLCs purification easier than using E. coli vectors. 
Currently Fan et al.’s laboratory can express recombinant human prolyl with human 
collagen α1 (III) chains in Pichia pastoris GS115 [50, 52]. In the future, the safer HLCs 
will be expressed in more eukaryotic expression vectors and will be purified more easily. 
 
5.3 Better purification and quality of HLC 
The purity of the HLCs is still not very high in present purification methods, such as 
salting-out method, ultrafiltration, ion exchange chromatography and some traditional 
purification methods. In the future, new purification methods should be developed. 
Besides, the low purity of the HLCs leads to screen the active HLCs inefficiently. In 
order to obtain active HLCs more efficiently, the frontal affinity chromatography-mass 
spectrometry (FAC-MS) [120] needs to be used to study the interaction between the 
HLC and other cell markers and therefore to improve the effectiveness of screening the 
active HLCs.  
 
5.4 Flexible designing of HLC 
The last but not the least, the variability of the potential HLC could be further achieved. 
As the gene template of the HLC is adjustable, designing new sequences to get variable 
HLCs with new properties should be exploited. For example, the length of the sequence 
of the collagens can be made longer, the HLCs will then be more easily cross-linked 
and the HLCs hydrogels will be more flexible, elastic, and stronger. More lysines can 
be added in the HLC sequence to promote the cells adhesion. Active peptides (RGD, 
elastin-like polypeptide etc.) [121-123], growth factors (VEGF, EGF etc.) and other 
proteins (heparin, integrin etc.) [124] can be used to recombine with the HLCs and 
express the multifunction fusion proteins. Based on the variability of the HLCs, the 
HLCs’ gene code can be designed to obtain recombinant HLCs with properties needed. 
For example, recombinant mini-collagen containing integrin binding site [125, 126], 
collagen-mimetic peptide sequences [127-130], etc. These purposed designed HLC 
could be used for optimising previous successful applications and further extending to 
other intended applications. 
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